In early February 2026, Illumina reported past fourth-quarter 2025 revenue of US$1,159 million and net income of US$334 ...

Illumina (ILMN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a ...

Genomics company Illumina (NASDAQ:ILMN) will be reporting results this Thursday after market close. Here’s what you need to ...

Illumina Inc. (Nasdaq: ILMN), a genomics and molecular diagnostics company headquartered in San Diego, closed in late January on its acquisition of Boulder-based biotech firm SomaLogic Inc.

Illumina (ILMN) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $0.86 per share a year ago. These figures are ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks ...

Illumina exhibits better profitability ratios than many of its peers, which indicates that the company could continue to invest in its operations. In Q3 2025, ILMN raised its EPS to $4.65-$4.75, ...

Raymond James Financial Inc. trimmed its stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 2.6% in the first quarter, Holdings Channel reports. The fund owned 368,635 shares of the life ...

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Illumina today and set a price target of $155.00. Arias covers the Healthcare sector, focusing on stocks such as Illumina, Exact ...

ILMN tops Q4 EPS and revenue estimates, posts 42% profit jump, but shares slide 10% on margin concerns despite 2026 growth outlook.